Th e eff ect of radiotherapy depends on optimal tumour oxygenation, as tumour hypoxia impairs the production of radiation-induced cytotoxic free radicals resulting in less tumour cell kill. Th e range of haemoglobin levels optimal for tumour oxygenation is 12-14 g/dl in women and 13-15 g/dl in men. It appears reasonable to elevate the haemoglobin level in anaemic cancer patients into this optimal range. Th is may be achieved with red blood cell transfusions (RBCT) or erythropoiesis stimulating agents (ESAs). However, RBCT have had negligible or even negative eff ect on patient outcome, possibly because RBCT induce immunosuppression or result in haemoglobin levels too high for optimal tumour oxygenation. Several randomized trials have demonstrated that patients irradiated for head-and-neck cancer had worse outcomes with ESAs than the control group. However, in the majority of these trials, over-treatment with ESAs resulted in haemoglobin levels above the optimal range. Tumour oxygenation is impaired by inappropriately high haemoglobin levels due to increased blood viscosity and decreased tumour cell perfusion. Th is concept is supported by the fi ndings of prospective studies in cervix cancer and esophageal cancer patients. In these studies the ESA administration was withheld at a haemoglobin level of 14 g/dl resulting in a positive eff ect of ESAs on treatment outcome. In summary, the eff ect of RBCT and particularly of ESAs during radiotherapy remains unclear. Further randomized trials are required. Until such trials are available, one should follow the ASCO and ESMO guidelines that are very conservative regarding the administration of ESAs during radiotherapy and chemoradiation.
Introduction
Controversy exists regarding the benefi t of anaemia correction during radiotherapy or chemoradiation of solid tumours.
Th e correction of anaemia can be achieved with red blood cell transfusions (RBCT) or erythropoiesis stimulating agents (ESAs). ESAs were demonstrated to be eff ective in improving fatigue and quality of life in patients with chemotherapy-induced anaemia over 15 years ago [1] . However, a recent metaanalysis including individual data from 13,933 cancer patients who participated in 53 randomized trials suggested that the use of ESAs was negatively associated with survival [2] . Similar results were found in another meta-analysis of 1,397 patients from fi ve randomized trials of radiotherapy for head-and-neck cancer [3] .
Th e limitation of both meta-analyses was the fact that the haemoglobin levels were pushed quite high by administration of ESAs in a considerable proportion of patients. Th is is particularly important in regards to the eff ectiveness of radiotherapy depending on optimal tumour oxygenation. According to radiobiological studies, tumour hypoxia impairs the production of radiation-induced cytotoxic free radicals leading to less DNA damage and tumour cell kill. Tumour oxygenation can be impaired by both anaemia and inappropriately high haemoglobin levels. High haemoglobin levels lead to increased blood viscosity and decreased perfusion of the tumour cells [4] . In addition, high haemoglobin levels predispose to pathologic clot formation. Haemoglobin levels must be 12-14 g/dl in women and 13-15 g/dl in men to achieve optimal tumour oxygenation and the best results from radiotherapy [5] . Th ese data have been confi rmed in a retrospective study of 108 oesophageal cancer patients, where haemoglobin levels during radiotherapy of 12-14 g/dl resulted in better 2-year loco-regional control than levels <12 g/dl or >14 g/dl (58% vs. 19% and 44%, p < 0.001) [6] . In another retrospective study of 181 patients with non-small cell lung cancer, haemoglobin levels during radiotherapy of <12 g/dl were associated with signifi cantly lower 2-year loco-regional control (29 vs. 41%, p = 0.004) and 2-year overall survival rates (41 vs. 58%, p = 0.013) when compared to haemoglobin levels during radiotherapy of ≥12 g/dl [7] .
Considering the radiobiological data regarding optimal tumour oxygenation, it appears reasonable to take a closer look at the studies investigating the administration of RBCT or ESAs in cancer patients treated with radiotherapy or chemoradiation.
Red blood cell transfusions (RBCT)
In 1995, Kelleher et al. suggested that worsening of tumour oxygenation due to anaemia could partially be reversed by administration of ESAs and RBCT in rats [8] . However, this effect was observed only for small tumours. In tumours ≥1.4 ml, anaemia correction did not signifi cantly improve tumour oxygenation. In a retrospective analysis of 204 patients irradiated for cervix cancer, the response to RBCT was disappointing [9] . Non-responders to RBCT had poor outcomes in terms of disease-free survival, pelvic control, and metastases-free survival. In another retrospective series of 605 patients irradiated for cervix cancer, RBCT were positively associated with treatment outcomes on univariate but not on multivariate analysis [10] . RBCT were negatively associated with survival in a series of 130 patients irradiated for cervix cancer (RR: 2.2; p < 0.001) [11] . It is possible that the haemoglobin levels in patients receiving RBCT were increased beyond the range considered optimal for tumour oxygenation. Unfortunately, the proportions of haemoglobin levels during radiotherapy of >14 g/dl in women and >15 g/dl in men were not stated. A recently published randomized study from Denmark investigated RBCT in 414 patients with squamous cell carcinoma of the head-and-neck (SCCHN) [12] . Pre-radiotherapy haemoglobin levels of <13 g/dl in women and <14.5 g/dl in men were defi ned as "low". RBCT was given to achieve haemoglobin levels in the "high" level range. Patients of the "high" level group had signifi cantly better loco-regional control (LRC), disease-specifi c survival (DSS), and overall survival (OS) than patients with "low" pre-radiotherapy haemoglobin levels. In the "low" level group, RBCT had no signifi cant benefi t on LRC (HR 0.99; p = 0.9), DSS (HR 1.07; p = 0.8), and OS (HR: 1.10; p = 0.6). Again, it is possible that the haemoglobin levels in the patients receiving RBCT were higher than the optimal range for tumour oxygenation. Th e unsatisfying results after RBCT may also be explained by the fact that RBCT can cause immunosuppression [13] . Because RBCT showed no benefi t or a negative impact on outcome after radiotherapy, radiation oncologists have been looking for alternative options to correct anaemia and improve tumour oxygenation during radiotherapy. Th is led to studies investigating the potential benefi t of ESAs.
Erythropoietin stimulating agents (ESAs)
Currently, radiation oncologists are hesitant to use ESAs with radiotherapy, as several randomized trials have demonstrated no benefi t or even a negative eff ect with respect to treatment outcomes. In 2003, the ENHANCE study was published that investigated the impact of epoetin beta in 351 patients irradiated for SCCHN [14] . Loco-regional control (RR: 1.69, p = 0.007) and survival (RR: 1.39, p = 0.02) were signifi cantly better in the placebo group than in the epoetin beta group. However, this study was criticized because the study groups were not balanced for relevant prognostic factors and because about one-third of patients were not treated per protocol. Furthermore, 82% of the patients in the epoetin beta groups had haemoglobin levels greater than the optimal range for tumour oxygenation in comparison to only 15% of patients in the placebo group. Taking into account the importance of optimal tumour oxygenation for the eff ectiveness of radiotherapy, it is no surprise that the placebo group did better than the (over-treated) epoetin beta group.
In 2007, the Radiation Th erapy Oncology Group 99-03 trial evaluated the role of weekly erythropoietin in 141 evaluable patients receiving concurrent chemoradiation and/or accelerated radiotherapy for SCCHN [15] . Th e 3-year locoregional failure rates were 44% in the erythropoietin group and 36% in the control group (p = 0.56). Th e 3-year overall survival rates were 56% and 57%, respectively.
Th e fi nal results of a randomized trial from Denmark (DAHANCA 10) were presented in 2009 [16] . Th e impact of darbepoetin alfa on treatment outcomes was investigated in 522 patients irradiated for SCCHN. Th e 5-year loco-regional control rates were 59% in the darbepoetin group and 68% in the control group, respectively (RR: 1.47, p = 0.04). Th e 5-year disease-free survival rates were 37% and 47%, respectively (RR: 1.32, p = 0.02), and the 5-year overall survival rates were 37% and 47%, respectively (RR: 1.20, p = 0.16). Th e target haemoglobin range in the DAHANCA 10 was 14-15.5 g/dl, which was like in the ENHANCE study and beyond the optimal range for tumour oxygenation. Th erefore, the prognosis of the patients in the control group was likely to be better than in the darbepoetin group due to over-treatment with darbepoetin.
In 2009, a randomized trial from the United Kingdom including 301 patients irradiated for SCCHN was published [17] . In contrast to the previous studies, an on-and-off strategy was used to avoid over-treatment with epoetin alfa. If the haemoglobin level became >15 g/dl, epoetin alfa was withheld until the haemoglobin level was <14.5 g/dl and restarted at 50% of the previous dose. Taking into account the optimal range for tumour oxygenation, the haemoglobin levels still were too high. According to that trial, the 5-year local diseasefree survival rates were 41% in the epoetin alfa group and 44% in the control group, respectively (p = 0.79), and the 5-year overall survival rates were 49% and 50%, respectively (p = 0.82).
In contrast to the four randomized trials of SCCHN, a recently published randomized trial of 257 patients receiving chemoradiation for cervix cancer showed a strong trend towards improved recurrence-free survival with the administration of epoetin alfa (HR: 0.66, p = 0.06) [18] . Overall survival was not signifi cantly diff erent (HR: 0.88, p = 0.63). A significant benefi t of epoetin alfa regarding recurrence-free survival was observed for patients with stage IB-IIA disease (HR: 0.39, p = 0.014) and patients having a complete resection (HR: 0.55, p = 0.039). Th ese results favouring epoetin alfa may be explained by the fact that in this trial, the epoetin alfa dose was reduced to 33% when the haemoglobin level reached 13 g/dl, and discontinued at 14 g/dl. A benefi t on treatment outcome with epoetin alfa was also observed in a prospective observational study of 96 patients receiving chemoradiation for oesophageal cancer [19] . In that study, epoetin alfa was started at haemoglobin levels <13 g/dl and stopped at 14 g/dl. Due to this on-and-off strategy, 64% patients of the epoetin alfa group had the majority of weekly haemoglobin levels within the optimal range of 12-14 g/dl compared to only 17% in the control group.
Th e results of all the previously mentioned studies and meta-analyses regarding the administration of ESAs might have been infl uenced by tumour expression of erythropoietin and its receptor EPO-R. A retrospective analysis of patients from the ENHANCE study suggested that tumour cell expression of EPO-R had a negative impact on treatment outcomes of patients receiving epoetin beta during radiotherapy [20] . Another retrospective study suggested that patients with low tumour expression of EPO-R and erythropoietin who received epoetin alfa during radiotherapy had better outcomes [21] . Furthermore, the results of the previously mentioned studies and meta-analyses might have been infl uenced by the patients' smoking habit, as smoking during radiotherapy has been shown to impair tumour oxygenation. Th is has been shown in particular for non-small cell lung cancer and headand-neck cancer [7, [22] [23] [24] . In a retrospective study of 181 patients with non-small cell lung cancer, loco-regional control at 2 years was better in patients who did not smoke than in patients who did smoke during radiotherapy (58% vs. 41%, p < 0.001) [7] . In another retrospective study of 151 patients with non-small cell lung cancer, patients who had stopped smoking at the time of initial consultation (prior to surgery and postoperative radiotherapy) had a signifi cantly better loco-regional control at 5 years (77% vs. 52%, p = 0.002) than patients who continued to smoke [22] . In the retrospective study of Kawakita et al. of 222 patients with cancer of the oral cavity, non-smokers and light smokers (<30 pack years) had signifi cantly better 5-year overall survival rates than moderate (31-59 pack years) and heavy smokers (≥60 pack years) [24] . Th e adjusted hazard ratios for moderate and heavy smokers versus light smokers were 2.44 (1.07-5.57, p = 0.034) and 2.66 (0.97-7.33, p = 0.058). Th e adjusted hazard ratio for non-smokers versus light smokers was 2.27 (0.84-6.15, p = 0.11).
ESAs have also been discussed in lymphoma patients, e.g. in patients receiving radiotherapy after autologous stem cell transplantation (ASCT). However, the data are very scarce. In 1998, Toren et al. reported grade 4 haematological toxicities requiring interruption of radiotherapy for more than one week in 11 of 93 patients (12%) who had received involved-fi eld irradiation after ASCT [25] . Patients with malignant lymphoma were at a signifi cantly higher risk of developing radiation-induced cytopenia than those patients with solid tumours (28% versus 5%, p < 0.05). Of the patients with a Non-Hodgkin's lymphoma, 8 of 14 (57%) patients who received the radiotherapy as planned and 6 of 7 (86%) patients who had a radiotherapy break of more than one week relapsed (p < 0.05). Th us, there may be a potential role for ESAs -If the increase of the haemoglobin level is <1 g/dl after 8-9 weeks, patients may be considered as non-responders, and ESA administration should be discontinued.
and G-CSF in order to avoid cytopenia-induced radiotherapy breaks. However, the scarce data available do not allow serious conclusions regarding the use of ESAs in these patients.
Conclusions
It appears important to maintain the haemoglobin levels within the optimal range for tumour oxygenation (12-14 g/dl in women and 13-15 g/dl in men) to achieve the maximum eff ect of radiotherapy. Th e role of RBCT and in particular of ESAs for irradiated cancer patients treated remains unclear. Randomized trials using cautious strategies of ESA administration during radiotherapy and considering tumour expression of EPO-R and erythropoietin are required. Such trials should consider the ASCO guidelines (ESA adult dosing recommendations given in Table 1 ) and ESMO guidelines (treatment recommendations according to the European Medicines Agency EMEA given in Table 2 ) [26, 27] . Both guidelines are extremely reserved regarding the use of ESAs in patients receiving radiotherapy. So are several meta-analyses [2, 28, 29] . Th e association between haemoglobin levels, tumour oxygenation, and eff ectiveness of radiotherapy remains complex and requires further investigation.
Take home message
It appears important to maintain the haemoglobin levels during radiotherapy within the optimal range for tumour oxygenation (12-14 g/dl in women and 13-15 g/dl in men) to achieve the best treatment outcome. Th e role of RBCT and ESAs remains unclear and needs to be clarifi ed by randomized trials employing strategies that aim at maintenance of an optimal haemoglobin concentration. Th e ASCO and ESMO guidelines aid the clinician when considering correction of anaemia in the individual patient.
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